Clinical Trial: A randomized, double-blind, placebo-controlled, dose-explore, multicenter phase II clinical study evaluating the efficacy and safety of HJY-ATRQβ-001 in participants with mild to moderate hypertension(TAVAR-2) (China)

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized, double-blind, placebo-controlled, dose-explore, multicenter phase II clinical study evaluating the efficacy and safety of HJY-ATRQβ-001 in participants with mild to moderate hypertension(TAVAR-2)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135587

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349335

Published by HT Digital Content Services with permission from Health Daily Dig...